Vedolizumab (Entyvio®)

Vedolizumab (Entyvio) is covered only for adults (≥18) with FDA‑approved moderately to severely active Crohn’s disease or ulcerative colitis when prescribed by or in consultation with a gastroenterologist (not covered for non‑FDA indications). Initial approval (6 months) requires documentation of the specified prior-treatment/surgical/fistula criteria (Crohn’s: enterocutaneous/rectovaginal fistula, ileocolonic resection, prior biologic, a conventional systemic therapy, systemic steroids, or steroid contraindication; UC: trial of ≥1 systemic or biologic agent or specified pouchitis therapies), dosing per label (300 mg IV at 0, 2, and 6 weeks then every 8 weeks), and renewals (12 months) require ≥6 months on therapy plus documented objective or symptomatic improvement.

"Entyvio is indicated in adults for the treatment of moderately to severely active ulcerative colitis."